Jonathan Slonin
Known title: Chief Clinical OfficerCIK: 0001875723
Associated companies
Transaction History
| PCRX | ▼ Sell | Open Market | 3,040 | $71K | 8/17/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 4,728 | $106K | 6/3/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,261 | $74K | 3/17/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 54,546 | $0 | 2/11/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 6,168 | $127K | 1/30/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 381 | $9K | 1/2/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,960 | $95K | 11/17/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 315 | $7K | 8/1/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 5,084 | $134K | 6/3/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 93,600 | $0 | 2/1/2025 | View on chart |
| PCRX | ▼ Sell | Open Market | 879 | $16K | 1/6/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 371 | $7K | 1/2/2025 | View on chart |
| PCRX | ▼ Sell | Open Market | 945 | $19K | 8/2/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 305 | $6K | 8/1/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,836 | $80K | 7/2/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 914 | $26K | 7/1/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 437 | $11K | 6/28/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 54,300 | $0 | 6/12/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,012 | $143K | 6/11/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 1,615 | $50K | 6/3/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 5,000 | $0 | 1/2/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 490 | $19K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 471 | $18K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 308 | $17K | 8/3/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 924 | $53K | 7/5/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 9,900 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 362 | $22K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,000 | $105K | 5/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.